Top

Published in:

01-11-2018 | Editorial

Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?

Authors: Matteo Bassetti, Mura Akova, Mario Tumbarello

Published in: Intensive Care Medicine | Issue 11/2018

Excerpt

The incidence of severe infections caused by Gram negative bacteria continues to increase, particularly with advances in medical care, and remains a major contributor to morbidity and mortality with variation between countries and between hospitals [1, 2]. The variable mortality rates of patients with severe infections caused by Gram negative bacteria depends largely on antibiotic resistance but also on differences involving the populations analyzed, including those related to age and underlying disease/comorbidity profiles [3]. Among Enterobacteriaceae, Klebsiella pneumoniae (Kp) is largely prevalent in patients admitted to acute and long-term care facilities, and has an outstanding propensity to develop antibiotic resistance [4]. The issue of Kp resistance, initially involving the class of cephalosporins due to the production of extended-spectrum β-lactamases (ESBL), has now been compounded by the emergence of strains that are also resistant to carbapenems [4, 5]. Kp is currently the most prevalent species among carbapenem-resistant (CR) Enterobacteriaceae, having become endemic in several countries so that the emergence of CR-Kp has been declared an ‘urgent’ and ‘critical’ threat by national and international organizations [6]. …

Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH III, Suffredini AF, Hooper DC, Fridkin S, Danner RL, National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI) (2018) Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. https://doi.org/10.1093/cid/ciy378 CrossRefPubMed

Ergönül Ö, Aydin M, Azap A, Başaran S, Tekin S, Kaya Ş, Gülsün S, Yörük G, Kurşun E, Yeşilkaya A, Şimşek F, Yılmaz E, Bilgin H, Hatipoğlu Ç, Cabadak H, Tezer Y, Togan T, Karaoğlan I, İnan A, Engin A, Alışkan HE, Yavuz SŞ, Erdinç Ş, Mulazimoglu L, Azap Ö, Can F, Akalın H, Timurkaynak F, Turkish Society of Clinical Microbiology and Infectious Diseases, Healthcare-Related Infections Study Group (2016) Healthcare-associated Gram-negative bloodstream infections: antibiotic resistance and predictors of mortality. J Hosp Infect. 94(4):381–385. https://doi.org/10.1016/j.jhin.2016.08.012 CrossRefPubMed

Jarrell AS, Kruer RM, Berescu LD, Pronovost PJ, Trivedi JB (2018) Factors associated with in-hospital mortality among critically ill surgical patients with multidrug-resistant Gram-negative infections. J Crit Care 43:321–326. https://doi.org/10.1016/j.jcrc.2017.10.035 CrossRefPubMed

Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M (2013) Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther. 11(10):1053–1063. https://doi.org/10.1586/14787210.2013.836057 (Epub 2013 Sep 27. Review. PubMed PMID: 24073806) CrossRefPubMed

Trecarichi EM, Cauda R, Tumbarello M (2012) Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiol 7(10):1173–1189. https://doi.org/10.2217/fmb.12.100 (Review. PubMed PMID: 23030423) CrossRefPubMed

Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF (2018) Carbapenemase-producing organisms: a global scourge. Clin Infect Dis 66(8):1290–1297. https://doi.org/10.1093/cid/cix893 CrossRefPubMed

Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, Viale P, Venditti M, Hernández-Torres A, Oliver A, Martínez-Martínez L, Calbo E, Pintado V, Gasch O, Almirante B, Antonio Lepe J, Pitout J, Akova M, Peña-Miralles C, Schwaber MJ, Tumbarello M, Tacconelli E, Origüen J, Prim N, Bou G, Giamarellou H, Bermejo J, Hamprecht A, Pérez F, Almela M, Lowman W, Hsueh PR, Navarro-San Francisco C, Torre-Cisneros J, Carmeli Y, Bonomo RA, Paterson DL, Pascual Á, Rodríguez-Baño J, REIPI/ESGBIS/INCREMENT Group (2017) Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due toextended-spectrum-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 72(3):906–913. https://doi.org/10.1093/jac/dkw513 CrossRefPubMed

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Pintado V, Doi Y, Tuon FF, Karaiskos I, Machuca I, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J, Investigators from the REIPI/ESGBIS/INCREMENT Group (2016) A Predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae. Mayo Clin Proc 91(10):1362–1371. https://doi.org/10.1016/j.mayocp.2016.06.024 CrossRef

Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E et al (2016) A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase producing Enterobacteriaceae. Antimicrob Agents Chemother 60:4159–4169CrossRef

10.

Muhammed M, Flokas ME, Detsis M, Alevizakos M, Mylonakis E (2017) Comparison between carbapenems and β-lactam/β-lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis. Open Forum Infect Dis 4(2):ofx099CrossRef

11.

Harris PNA, Tambyah PA, Lye DC, MERINO Trial Investigators, Australasian Society for Infectious Disease Clinical Research Network et al (2018) Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with Escherichia coli or Klebsiella pneumoniae bloodstream infection and ceftrixone resistance: a randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2018.12163 CrossRefPubMedPubMedCentral

12.

GiViTI Steering Committee, Bertolini G, Nattino G, Tascini C et al (2018) Mortality attributable to different Klebsiella susceptibility patterns and to the coverage of empirical antibiotic therapy: a cohort study on patients admitted to the ICU with infection. Intensive Care Med 44(10):1709–1719. https://doi.org/10.1007/s00134-018-5360-0 CrossRef

13.

Tumbarello M, Trecharichi EM, Corona A et al (2018) Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae. Clin Infect Dis. https://doi.org/10.1093/cid/ciy492 CrossRefPubMed

14.

Shields RK, Potoski BA, Haidar G et al (2016) Clinical outcomes, drug toxicity, and emergence of ceftazidime/avibactamresistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63:1615–1618CrossRef

15.

Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A (2017) Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med 43(10):1464–1475CrossRef

16.

Bassetti M, Righi E, Carnelutti A, Graziano E, Russo A (2018) Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control. Expert Rev Anti Infect Ther 12:1–13. https://doi.org/10.1080/14787210.2018.1522249 CrossRef

Title: Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?
Authors: Matteo Bassetti
Mura Akova
Mario Tumbarello
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 11/2018
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-018-5390-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2018

Moving albumin into the small volume resuscitation era

Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial

An unexpected blood thief: the subacute presentation of a spontaneous Ilio-iliac arterio-venous fistula

Do trials that report a neutral or negative treatment effect improve the care of critically ill patients? Yes

Inherent value of baseline measures when assessing the trajectory of health-related quality of life among children surviving critical illness

Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with sepsis: a randomized clinical trial